Hemogenyx reverses into Silver Falcon, issues shares to Cornell Uni

Iain Gilbert WebFG News | 05 Oct, 2017 10:15 | | |

ep laboratoriobioquimica clinicala clinica universidadnavarra

Hemogenyx Pharmaceuticals

2.88

17:18 22/11/17
0.00%
0.00

Preclinical-stage biotechnology company Hemogenyx began trading on on Thursday after reversing into fully listed cash shell Silver Falcon.

Brooklyn-based Hemogenyx, which is primarily focused on developing new treatments for blood diseases such as leukaemia, lymphoma and blood marrow failure, joined with an initial market cap of £12.46m after Silver Falcon issued 228.5m shares to acquire the business for £8m and then £2m was raised through the issue of 57m new ordinary shares in a placing and subscription offer at 3.5p per share that was approved by shareholders a day earlier.

The company plans use the proceeds, which take it's cash balance up to around £3.1m, to complete its IND-enabling preclinical development and to finance further preclinical development of its Hu-PHEC cell therapy product.

Hemogenyx's therapies are aimed to do away with the need for chemotherapy or radiation before bone marrow transplants, which would eradicate the need to find a matching donor.

The company also announced that Cornell University will receive payment of the $372,350 sum due to it on the change of control of Hemogenyx half in new shares and half in cash, rather than all in cash as originally expected.

The sum related to the patents covering the method of isolation of post-natal hemogenic endothelial cells, invented by Vladislav Sandler, chief executive and co-founder, while Cornell's shares will give it a 1.13% stake in the company.

Dr Sandler, who is also a research assistant professor at the State University of New York, said he was excited by the prospect of taking the therapies forward into human trials and beyond thanks to the fund-raising.

"We believe the products we are developing should greatly reduce the dangers of patient conditioning procedures and create a new form of blood stem cell transplantation which, if successful, would greatly enhance the long-term success of stem cell replacement therapy. We look forward to keeping shareholders fully abreast of developments as they occur."

As 0920 BST, Silver Falcon shares had dropped back 2.67% to 3.65p.

More news

00:20 US close: Wall Street mixed ahead of Thanksgiving holiday

Wall Street finished mixed on Wednesday, following the record highs set the day before and amid lighter-than-usual trading volumes ahead of the Thanksgiving holiday on Thursday.

22 Nov Jefferies upgrades Kingfisher to 'buy', raises target price

Analysts at Jefferies upgraded home improvement products retailer Kingfisher (KGF) to 'buy' from its previous 'hold' rating on Wednesday, raising its target price from 310p to 400p along the way.

22 Nov Europe close: German stocks give back gains amid political impasse

Stocks ended the session modestly lower as traders waited for the release of the minutes of the US Federal Reserve's last rate-setting meeting in the evening and monitored the news-flow out of Germany, amid speculation that a 'grand coalition' between Germany's two main political parties, the centre-right CDU/CSU and the Socialist SPD, may yet be possible.

22 Nov Lebanon prime minister Hariri retracts resignation

Saad al-Hariri has revoked his resignation as Lebanon's prime minister, according to a local news report on Wednesday.

22 Nov Budget: Planning probe spooks builders, mixed reaction for stamp duty cut

A range of new housing policies were proposed by Chancellor Philip Hammond in his Budget statement, including more funds for smaller housebuilder, a probe into potential holding of land by major housebuilders and a stamp duty cut for first-time buyers.

22 Nov US open: Shares hold ground ahead of FOMC minutes

Wall Street is holding its ground following the record highs set the day before, albeit amid lighter than usual trading volumes ahead of the Thanksgiving Holiday on Thursday, with investors looking to the release of the minutes of the most recent meeting of the Federal Open Market Committee.

22 Nov London close: Stocks higher on UK budget

Shares closed higher on Wednesday as investors sifted through corporate releases as well as the Autumn Budget.

22 Nov FTSE 250 movers: Qinetiq boosted by Berenberg note as Thomas Cook tanks

The FTSE 250 index was up around 0.50% on the day in which Chancellor Philip Hammond revealed his budget for the upcoming year.

22 Nov Higher margins offset declining sales volumes at Cambria

Motor dealer Cambria Automobiles managed to successfully grow profit and revenue throughout the financial year, as per-unit profits counteracted a slide in sales volumes.

22 Nov First production at Texas asset transforms Pantheon Resources into full-cycle energy and power business

Oil and gas exploration firm Pantheon Resources announced "another year of progress" in its full-year results on Wednesday, as it completed the transition from a pure-play exploration company to a full-cycle energy and power business.